[Specific immunotherapies in the treatment of cancers].
Denis H, Davoine C, Bermudez E, Grosjean G, Schwager M, Ifrah N, Dahan M, Negellen S.
Denis H, et al.
Bull Cancer. 2019 Jan;106(1):37-47. doi: 10.1016/j.bulcan.2018.12.007. Epub 2019 Jan 11.
Bull Cancer. 2019.
PMID: 30638899
Review.
French.
The clinical development of these therapies is still in full swing: in July 2017, more than 1 500 clinical trials were evaluating anti-PD-1, anti-PD-L1 and anti-CTLA-4 drugs in about twenty different locations and this number continues to increase. In the short term in Fra …
The clinical development of these therapies is still in full swing: in July 2017, more than 1 500 clinical trials were evaluating anti-PD-1, …